Department of Medicine, Division of Hematology, Karolinska University Hospital Solna, SE-171 76, Stockholm, Sweden.
Expert Rev Mol Diagn. 2011 Jul;11(6):593-603. doi: 10.1586/erm.11.44.
The manifestations of bone involvement in patients with multiple myeloma (MM) can have devastating clinical effects and increase mortality. Recent studies demonstrate that patients with the precursor conditions smoldering MM (SMM) and monoclonal gammopathy of undetermined significance (MGUS) show evidence of bone disease and increased risk of fractures. The understanding of the pathogenesis of bone disease in MM has expanded in recent years. The traditional skeletal survey will probably be replaced by newer and more sensitive imaging techniques, which may have a prognostic impact and change our definition of MGUS and SMM. Bisphosphonates are recommended to prevent skeletal events in patients with MM, and have also been studied in SMM and MGUS. This article summarizes the current knowledge of bone disease in plasma cell disorders, and discusses the current standard and future role of novel imaging techniques, as well as the evidence and current guidelines for bisphosphonates in MM, SMM and MGUS.
多发性骨髓瘤(MM)患者的骨骼受累表现可能具有破坏性的临床影响,并增加死亡率。最近的研究表明,冒烟型多发性骨髓瘤(SMM)和意义未明的单克隆丙种球蛋白病(MGUS)患者存在骨骼疾病的证据,并且骨折风险增加。近年来,对 MM 骨骼疾病发病机制的认识已经扩大。传统的骨骼检查可能会被更新、更敏感的成像技术所取代,这些技术可能具有预后影响,并改变我们对 MGUS 和 SMM 的定义。双膦酸盐被推荐用于预防 MM 患者的骨骼事件,并且也在 SMM 和 MGUS 中进行了研究。本文总结了浆细胞疾病中骨骼疾病的当前知识,并讨论了新型成像技术的当前标准和未来作用,以及在 MM、SMM 和 MGUS 中使用双膦酸盐的证据和当前指南。